Lactobacillus Johnsonii Supplementation in Adults With T1D

Type 1 Diabetes (T1D) Clinical Trial

Official title:
Evaluation of Safety, Tolerability and Immunological Responses to Lactobacillus Johnsonii N6.2 Supplementation in Adults With Diabetes Type 1

Status Recruiting

Clinical Trial Summary

While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03961347
Study type	Interventional
Source	University of Florida
Contact	Michael Haller, MD
Phone	352-273-9264
Email	hallemj@peds.ufl.edu
Status	Recruiting
Phase	Phase 2
Start date	February 1, 2020
Completion date	June 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06315725` - Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients With Type 1 Diabetes (T1D)
Recruiting	`NCT03961854` - Lactobacillus Johnsonii in Children and Adolescents With T1D	Phase 2
Completed	`NCT01369082` - Extended Follow-Up After Islet Transplantation in T1D	N/A